AstraZeneca has halted its phase 3 lung cancer trial of volrustomig (a bispecific combination strategy) after interim data showed it was unlikely to improve survival versus pembrolizumab (Keytruda) and standard comparator therapy. The decision follows a review by an Independent Data Monitoring Committee, prompting the company to stop enrollment and development activity in the study as reported. The latest cut deepens AstraZeneca’s pipeline stress in oncology, where competitive positioning against PD-1-based regimens is increasingly central. The program’s stoppage narrows the company’s near-term options in lung cancer and increases scrutiny on remaining late-stage assets and biomarkers tied to response. For clinicians and partners, the change underscores how quickly late-stage oncology plans can shift when efficacy signals don’t materialize early enough to support continued follow-through. The company’s next updates will likely focus on whether any subgroups show differential benefit and what that means for future combination strategies. Separately, AstraZeneca also disclosed a related earlier decision to stop a late-stage lung cancer treatment trial involving volrustomig after similar concerns about survival benefit surfaced, consolidating the message that the mechanism has not translated into the durability expected at phase 3.